What I find most amusing is why anyone is expecting Dr. Odidi and the new CFO to do an offering that could/would effect/jeopardize their NAZ listing given the fact that there's still several options that can be easily explored as outlined by many posters here over the recent weeks.
We're not talking about needing a lot of money for the CAT 2 and 3 HAP studies after all...and we're on the verge of IPCI attaining positive net income right now during these 1st few weeks of their 2017 fiscal Q4.
I'm not saying they won't do an offering but reading some of the posts saying they definitely will is amusing...because Dr. Odidi's already had 8 years to engage in reckless dilution offerings and has done his utmost to keep dilution to an absolute minimum the entire time right.
So although we still need plenty of answers from IPCI mgmt. on how they actually plan on paying for the necessary HAP studies for nasal and oral on Rexista...it's equally absurd for any long standing IPCI long to suddenly assume that Dr. Odidi is suddenly gonna jeopardize his NAZ listing by engaging in some mystery dilution offering that would/will drive the share price down and result in IPCI's NAZ listing becoming a real issue for concern right.
News 
Market Data 
Discover 
